

Elisabeth QUOIX

Elisabeth Quoix is Professor of Pneumology in the Department of Chest Diseases of the University Hospital of Strasbourg. Her clinical work focuses on the diagnosis and management of lung cancer, including the use of chemotherapy. She was a resident at the Strasbourg University Hospital (1976-1980) and received her medical degree from Strasbourg, Louis Pasteur University in 1980, after which she became "Chef de Clinique-Assistant des Hôpitaux" until 1984. She then spent several months at the McGill Cancer Center of Montreal (Quebec, Canada) as a research assistant, where she participated in research on the design and methodology of clinical trials, including the impact of biases and assessment of response. In 1985 she was appointed "Praticien Hospitalier" at the University Hospital of Strasbourg, and was nominated as a Professor in 1990. She is now Head of the Department of Pneumology in the University Hospital of Strasbourg. Dr. Quoix was the secretary of the "Groupe d'Oncologie Thoracique" of the French Society of Pneumology (1992-1995) and was the first President of the IFCT (French Intergroup of Thoracic Oncology) from its creation in 1999 until 2006. She is a now Past-President and a member of the Scientific Council of the IFCT. Dr. Quoix is currently involved as an investigator or coordinator in several clinical trials investigating treatment strategies in lung cancer, as well as a number of early phase trials of novel agents for lung cancer, with pharmaceutical industry sponsorship. She is also involved in epidemiological studies of the implementation of "state of the art" techniques of diagnosis and treatment among the general population of patients with lung cancer. Dr. Quoix is the author or co-author of more than 200 peer-reviewed papers, mainly in the field of lung cancer. She had contributed to several textbooks on the subject of pneumology and lung cancer. She is member of several working and scientific societies and member of the Editorial Board of several journals

Most relevant/recent peer-reviewed publications (last 5 years):

1. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. *Lancet Oncol.* 2016 Jul;17(7):984-93.
2. Post-operative survival of patients with lung cancer. Quoix E. *Lancet Oncol.* 2016 Jun;17(6):697-8
3. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. *Lancet Oncol.* 2016 May;17(5):642-50.
4. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Filip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM. *Lancet Oncol.* 2016 Feb;17(2):212-23
5. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Filip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. *N Engl J Med.* 2014 Dec 4;371(23):2167-77.